ProtonDx, an in vitro diagnostics company designing, manufacturing and marketing rapid, accurate, multi-pathogen, point-of-need diagnostic solutions, has appointed Leigh Howes as its new head of sales.
Howes is a commercially astute leader with more than 20 years of experience in the life science, diagnostics and clinical markets. He brings a proven track record of success to ProtonDx, delivering consistent growth, focused on achievement and a structured approach to strategy deployment.
As leader of the Commercial Sales team, Howes will have a pivotal role in setting-up distribution partners and direct sales in Europe and countries that accept the CE-IVD mark. This follows ProtonDx’s successful CE IVD marking for its innovative Dragonfly in vitro diagnostic system earlier this year.
Howes commented: “I am honoured and thrilled to be joining ProtonDx, and look forward to working with a talented and highly dedicated team. By introducing molecular testing at the point-of-care, our flagship product, Dragonfly, delivers numerous potential benefits for healthcare professionals and caregivers – ultimately improving patient outcomes. I look forward to helping realise ProtonDx and Dragonfly’s huge potential and to build on the Company’s existing successes while solidifying its position as a significant commercial player.”
Dragonfly is a portable, rapid molecular diagnostic system able to identify multiple viral pathogens at the point of need. Its revolutionary approach allows severe acute respiratory syndrome coronavirus 2 (SARS CoV 2), influenza A virus (IAV), influenza B virus (IBV), respiratory syncytial virus (RSV) and human rhinovirus (HRV) to be detected in a single test. The system is poised to help revolutionise rapid infectious disease detection and tracking worldwide